Danielle Cohen, Liesbeth M Hondelink, Nienke Solleveld-Westerink, Sandra M Uljee, Dina Ruano, Anne-Marie Cleton-Jansen, Jan H von der Thüsen, S Rajen S Ramai, Pieter E Postmus, Jacob F Graadt van Roggen, Bart P C Hoppe, Pieter C Clahsen, Klaartje W Maas, Els J M Ahsmann, Alexandra Ten Heuvel, Frank Smedts, Ronald N van Rossem, Tom van Wezel
INTRODUCTION: Frequently, patients with locally advanced or metastatic NSCLC are screened for mutations and fusions. In most laboratories, molecular workup includes a multitude of tests: immunohistochemistry (ALK, ROS1, and programmed death-ligand 1 testing), DNA sequencing, in situ hybridization for fusion, and amplification detection. With the fast-emerging new drugs targeting specific fusions and exon-skipping events, this procedure harbors a growing risk of tissue exhaustion. METHODS: In this study, we evaluated the benefit of anchored, multiplexed, polymerase chain reaction-based targeted RNA sequencing (RNA next-generation sequencing [NGS]) in the identification of gene fusions and exon-skipping events in patients, in which no pathogenic driver mutation was found by DNA-based targeted cancer hotspot NGS (DNA NGS)...
June 2020: Journal of Thoracic Oncology